Department of infectious and tropical diseases, Besançon University Hospital, Besançon, F-25000, France.
Department of Infectious Diseases, Nord Franche-Comté Hospital, Trevenans, 90400, France.
Eur J Clin Microbiol Infect Dis. 2024 Nov;43(11):2107-2115. doi: 10.1007/s10096-024-04923-7. Epub 2024 Aug 21.
Few data have been published on the efficacy of linezolid in enterococcal urinary tract infection (e-UTI). The aims of this study were to describe the characteristics of patients with enterococci UTI treated with linezolid, and to evaluate the efficacy and the tolerance of linezolid treatment.
An observational multicentre retrospective study was conducted in 5 hospitals in France. Patients were included if they met the following criteria: ≥18 years, clinical and microbiological criteria for enterococcal UTI and linezolid treatment > 48 h. Primary outcome was clinical failure.
Eighty-one patients were included between January 2015 and December 2021. The median age was 73.0 [64; 83] years and 47 (58%) were men. The median Charlson comorbidity index was 3.00 [2; 6]. E. faecium was reported in 65 (80%) cases and E. faecalis in 26 cases (32%). Polymicrobial infections occurred in 41 (51%) cases. No enterococci was resistant to vancomycin. Before linezolid prescription an empiric antimicrobial treatment was started in 48 (59%) cases and was effective against enterococci in 19/48 (39.5%) patients for a median of 3.5 days [2.0; 4.0]. The median duration of linezolid antibiotic treatment was 13 days [10; 14]. Three adverse events were reported, none were serious but one led to discontinuation of treatment. Treatment failure was reported in 2 cases (2.5%).
This study provides evidence for efficacy and safety of linezolid in enterococcal UTI.
关于利奈唑胺治疗肠球菌尿路感染（e-UTI）的疗效，相关数据较少。本研究旨在描述接受利奈唑胺治疗的肠球菌尿路感染患者的特征，并评估利奈唑胺治疗的疗效和耐受性。
这是一项在法国 5 家医院进行的观察性多中心回顾性研究。符合以下标准的患者入选：年龄≥18 岁，具有临床和微生物学诊断肠球菌 UTI 的标准，并接受利奈唑胺治疗超过 48 小时。主要结局为临床失败。
2015 年 1 月至 2021 年 12 月期间共纳入 81 例患者。患者中位年龄为 73.0[64;83]岁，47 例（58%）为男性。中位 Charlson 合并症指数为 3.00[2;6]。65 例（80%）为屎肠球菌感染，26 例（32%）为粪肠球菌感染。41 例（51%）为混合感染。所有肠球菌均对万古霉素敏感。利奈唑胺治疗前，48 例（59%）患者接受了经验性抗菌治疗，19/48 例（39.5%）患者的治疗有效，抗菌治疗中位持续时间为 3.5 天[2.0;4.0]。利奈唑胺治疗的中位持续时间为 13 天[10;14]。报告了 3 例不良事件，均不严重，但其中 1 例导致治疗中断。2 例（2.5%）患者治疗失败。
本研究提供了利奈唑胺治疗肠球菌 UTI 的疗效和安全性证据。
